Inhibitor Therapeutics (formerly known as HedgePath Pharmaceuticals) is a pharmaceutical company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. It develops SUBA-Itraconazole, a patented, oral formulation of the currently marketed, anti-fungal drug, Itraconazole, for treatment of prostate and lung cancers.